French techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.
UK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate resources on its central nervous system (CNS) pipeline.
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.
Sanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired through the acquisition of Translate Bio in 2021.
AstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade ago.
A stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation.
Global science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues to expand its Munich site despite geopolitical tensions, and why trust, quality, and international collaboration are essential for the future of drug discovery.
Welsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging from stealth.
Spanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030 through its two specialist venture funds.
Targeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting chimeras) has evolved into a broader “induced proximity” field that now includes molecular glue degraders, degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs), RNA degraders and other proximity-based therapeutics.
Bayer AG
Wuxi AppTec